After a successful cross-country collaboration with the HydraFacial Nation World Tour, Colorescience®, the leading dermatologist-recommended skincare and cosmetics company, is excited to announce the next partnership between the two companies beginning in August 2018 that fully integrates Colorescience®’s into the PERK experience.
Colorescience® is pleased to announce that the US Patent and Trademark Office (USPTO) has granted a patent (US Patent No. 9,956,163) for the company’s innovative LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment Perfector®.
Solsys Medical, LLC (“Solsys”) (formerly known and doing business as Soluble Systems, LLC) (“Soluble Systems”), which markets TheraSkin®, a cellular and tissue-based product for regenerative wound healing, announced today the appointment of Arti Balar Masturzo, M.D as its Chief Medical Officer.
Insight Medical Systems has teamed up with Onkos Surgical, Inc. to explore opportunities to apply Insight Medical’s ARVIS™ (Augmented Reality Visualization and Information System) in musculoskeletal oncology. The companies are working on a pilot project to assess the technology for use in tumor surgery.
Innovative Health announced on Monday that it scored FDA clearance to reprocess St. Jude Medical’s ViewFlex Xtra Diagnostic Ultrasound Catheter. “Reprocessing is changing,” Rick Ferreira, CEO of Innovative Health, told HCB News. “It used to be about mimicking manufacturer technique on low-complexity devices late in their life cycle. SUD reprocessing is increasingly about understanding clinical …
Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.
Genoptix, Inc., a leading oncology diagnostic laboratory today announced that Rosetta Genomics’ stockholders have approved the acquisition of Rosetta Genomics by Genoptix. Genoptix will immediately begin marketing, selling and distributing the complete Rosetta Genomics portfolio and will ensure the uninterrupted availability of these important products for physicians and patients. Genoptix previously purchased Rosetta Genomics’ precision …
Easing adoption, accelerating commoditization and lowering costs. That’s how it works everywhere else. Why not in healthcare? In my interview of experts from Innovative Health, the largest U.S. medical device reprocessor specializing in cardiology, they all reinforced the same point: hospital decision-makers still must turn the tables on the manufacturer.
Colorescience® is proud to announce the addition of two new members to its Board of Directors, David Olsen and Ty Stiklorius.
Onkos Surgical, Inc. announced today that it signed a 4-year agreement with 3D Systems (NYSE: DDD) to advance the delivery of personalized surgical solutions and help improve patient outcomes.